Apmonia Therapeutics announces a 4 M€ fundraising round
Apmonia Therapeutics announces a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP-01) Success for Apmonia Therapeutics’ technology